PLRX

Pliant Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 3/10
  • Momentum↓ 2/10
Pliant Therapeutics sales and earnings growth
PLRX Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 14.07%
  • FCF Y/Y↓ -16.10%
Pliant Therapeutics gross and profit margin trends
PLRX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -62.10%
Pliant Therapeutics net debt vs free cash flow
PLRX Risk
Great
  • Debt / Equity↓ 0.3
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -52.9

Pliant Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗